218 related articles for article (PubMed ID: 29464331)
21. Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma.
Seibel I; Cordini D; Hager A; Tillner J; Riechardt AI; Heufelder J; Davids AM; Rehak M; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1787-92. PubMed ID: 27376824
[TBL] [Abstract][Full Text] [Related]
22. Genetic findings in treatment-naïve and proton-beam-radiated iris melanomas.
Krishna Y; Kalirai H; Thornton S; Damato BE; Heimann H; Coupland SE
Br J Ophthalmol; 2016 Jul; 100(7):1012-1016. PubMed ID: 27098748
[TBL] [Abstract][Full Text] [Related]
23. Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes.
Shields CL; Shah SU; Bianciotto CG; Emrich J; Komarnicky L; Shields JA
Ophthalmology; 2013 Jan; 120(1):55-61. PubMed ID: 22980742
[TBL] [Abstract][Full Text] [Related]
24. Limbal Stem Cell Preservation During Proton Beam Irradiation for Diffuse Iris Melanoma.
Singh AD; Dupps WJ; Biscotti CV; Suh JH; Lathrop KL; Nairn JP; Shih H
Cornea; 2017 Jan; 36(1):119-122. PubMed ID: 27755196
[TBL] [Abstract][Full Text] [Related]
25. Secondary Glaucoma due to Iridescent Crystalline Particles Masquerading as Refractory Hypertensive Uveitis in an Eye With Irradiated Iris Melanoma.
Chahal R; Mohite AA; Heimann H; Bansal A
J Glaucoma; 2018 Apr; 27(4):385-388. PubMed ID: 29394206
[TBL] [Abstract][Full Text] [Related]
26. Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma.
Wuestemeyer H; Sauerwein W; Meller D; Chauvel P; Schueler A; Steuhl KP; Bornfeld N; Anastassiou G
Graefes Arch Clin Exp Ophthalmol; 2006 Apr; 244(4):438-46. PubMed ID: 16133022
[TBL] [Abstract][Full Text] [Related]
27. Regression Patterns of Iris Melanoma after Palladium-103 (
Chaugule SS; Finger PT
Ophthalmology; 2017 Jul; 124(7):1023-1030. PubMed ID: 28377036
[TBL] [Abstract][Full Text] [Related]
28. Use of Ruthenium-106 Brachytherapy for Iris Melanoma: The Scottish Experience.
Agraval U; Sobti M; Russell HC; Lockington D; Ritchie D; Cauchi P; Kemp EG; Chadha V
Br J Ophthalmol; 2018 Jan; 102(1):74-78. PubMed ID: 28600302
[TBL] [Abstract][Full Text] [Related]
29. Side effects of proton beam therapy of choroidal melanoma in dependence of the dose to the optic disc and the irradiated length of the optic nerve.
Riechardt AI; Stroux A; Seibel I; Heufelder J; Zeitz O; Böhmer D; Joussen AM; Gollrad J
Graefes Arch Clin Exp Ophthalmol; 2020 Nov; 258(11):2523-2533. PubMed ID: 32533280
[TBL] [Abstract][Full Text] [Related]
30. Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field).
Oxenreiter MM; Lane AM; Aronow MB; Shih H; Trofimov AV; Kim IK; Gragoudas ES
Br J Ophthalmol; 2022 Apr; 106(4):518-521. PubMed ID: 33355171
[TBL] [Abstract][Full Text] [Related]
31. Proton Beam Irradiation: A Safe Procedure in Postequatorial Extraocular Extension From Uveal Melanoma.
Seibel I; Riechardt AI; Erb-Eigner K; Böker A; Cordini D; Heufelder J; Joussen AM
Am J Ophthalmol; 2018 Jul; 191():49-53. PubMed ID: 29655645
[TBL] [Abstract][Full Text] [Related]
32. Proton therapy for reirradiation of progressive or recurrent chordoma.
McDonald MW; Linton OR; Shah MV
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1107-14. PubMed ID: 24267972
[TBL] [Abstract][Full Text] [Related]
33. Repeat Episcleral Plaque Brachytherapy: Clinical Outcomes in Patients Treated for Locally Recurrent Posterior Uveal Melanoma.
King B; Morales-Tirado VM; Wynn HG; Gao BT; Ballo MT; Wilson MW
Am J Ophthalmol; 2017 Apr; 176():40-45. PubMed ID: 28048976
[TBL] [Abstract][Full Text] [Related]
34. Radiotherapeutic and surgical management of iris melanoma: A review.
Popovic M; Ahmed IIK; DiGiovanni J; Shields CL
Surv Ophthalmol; 2017; 62(3):302-311. PubMed ID: 28062196
[TBL] [Abstract][Full Text] [Related]
35. Transpalpebral proton beam radiotherapy of choroidal melanoma.
Konstantinidis L; Roberts D; Errington RD; Kacperek A; Heimann H; Damato B
Br J Ophthalmol; 2015 Feb; 99(2):232-5. PubMed ID: 25138766
[TBL] [Abstract][Full Text] [Related]
36. Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas : Ablative dose PBT for NSCLC.
Lee SU; Moon SH; Cho KH; Pyo HR; Kim JY; Kim DY; Kim TH; Suh YG; Kim YJ
Strahlenther Onkol; 2016 Sep; 192(9):649-57. PubMed ID: 27282279
[TBL] [Abstract][Full Text] [Related]
37. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO).
Dendale R; Lumbroso-Le Rouic L; Noel G; Feuvret L; Levy C; Delacroix S; Meyer A; Nauraye C; Mazal A; Mammar H; Garcia P; D'Hermies F; Frau E; Plancher C; Asselain B; Schlienger P; Mazeron JJ; Desjardins L
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):780-7. PubMed ID: 16647221
[TBL] [Abstract][Full Text] [Related]
38. Photodynamic therapy for recurrent hyphema after proton beam radiotherapy of iris melanoma.
Trichopoulos N; Damato B
Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1573-5. PubMed ID: 17429673
[TBL] [Abstract][Full Text] [Related]
39. Ciliary body melanoma with limited nodular extrascleral extension and diffuse iris-angle infiltration treated by whole anterior segment plaque radiotherapy.
Gray ME; Corrêa ZM; Augsburger JJ; Barrett W
Int Ophthalmol; 2007 Aug; 27(4):273-6. PubMed ID: 17468833
[TBL] [Abstract][Full Text] [Related]
40. Multifocal iris melanoma treated with total anterior segment palladium-103 plaque radiation therapy.
Petousis V; Finger PT; Milman T
Graefes Arch Clin Exp Ophthalmol; 2011 Jun; 249(6):937-40. PubMed ID: 21222214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
